Chong Kun Dang Pharmaceutical Corp. (185750.KS)
KRW 78600.0
(-0.38%)
KRW 78600.0
(-0.38%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 219.76 Billion KRW | -6.78% |
| 2022 | 235.73 Billion KRW | -0.56% |
| 2021 | 237.05 Billion KRW | 74.12% |
| 2020 | 136.14 Billion KRW | 15.32% |
| 2019 | 118.05 Billion KRW | 13.01% |
| 2018 | 104.47 Billion KRW | 1.96% |
| 2017 | 102.45 Billion KRW | -17.75% |
| 2016 | 124.56 Billion KRW | 0.0% |
| 2015 | 124.56 Billion KRW | 0.0% |
| 2014 | 124.56 Billion KRW | 0.0% |
| 2013 | 124.56 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 216.08 Billion KRW | -0.41% |
| 2024 Q1 | 216.98 Billion KRW | -1.27% |
| 2023 Q2 | 237.32 Billion KRW | -2.69% |
| 2023 Q1 | 243.88 Billion KRW | 3.46% |
| 2023 FY | 219.76 Billion KRW | -6.78% |
| 2023 Q4 | 219.76 Billion KRW | -0.66% |
| 2023 Q3 | 221.22 Billion KRW | -6.79% |
| 2022 Q3 | 240.59 Billion KRW | 0.93% |
| 2022 Q2 | 238.37 Billion KRW | 0.56% |
| 2022 FY | 235.73 Billion KRW | -0.56% |
| 2022 Q1 | 237.04 Billion KRW | -0.01% |
| 2022 Q4 | 235.73 Billion KRW | -2.02% |
| 2021 Q1 | 137.47 Billion KRW | 0.98% |
| 2021 Q4 | 237.05 Billion KRW | -0.23% |
| 2021 FY | 237.05 Billion KRW | 74.12% |
| 2021 Q3 | 237.59 Billion KRW | 73.66% |
| 2021 Q2 | 136.81 Billion KRW | -0.47% |
| 2020 Q2 | 163.62 Billion KRW | 39.69% |
| 2020 Q3 | 162.17 Billion KRW | -0.89% |
| 2020 FY | 136.14 Billion KRW | 15.32% |
| 2020 Q1 | 117.14 Billion KRW | -0.78% |
| 2020 Q4 | 136.14 Billion KRW | -16.05% |
| 2019 FY | 118.05 Billion KRW | 13.01% |
| 2019 Q1 | 106.98 Billion KRW | 2.4% |
| 2019 Q4 | 118.05 Billion KRW | 6.49% |
| 2019 Q3 | 110.86 Billion KRW | 1.93% |
| 2019 Q2 | 108.76 Billion KRW | 1.67% |
| 2018 Q2 | 105.8 Billion KRW | 1.03% |
| 2018 FY | 104.47 Billion KRW | 1.96% |
| 2018 Q4 | 104.47 Billion KRW | 0.34% |
| 2018 Q3 | 104.11 Billion KRW | -1.59% |
| 2018 Q1 | 104.72 Billion KRW | 2.21% |
| 2017 FY | 102.45 Billion KRW | -17.75% |
| 2017 Q4 | 102.45 Billion KRW | 0.0% |
| 2016 Q2 | 158.56 Billion KRW | 27.29% |
| 2016 Q1 | 124.56 Billion KRW | 0.0% |
| 2016 FY | 124.56 Billion KRW | 0.0% |
| 2016 Q3 | 149.56 Billion KRW | -5.68% |
| 2015 Q2 | 124.56 Billion KRW | 0.0% |
| 2015 Q4 | 124.56 Billion KRW | 0.0% |
| 2015 Q1 | 124.56 Billion KRW | 0.0% |
| 2015 Q3 | 124.56 Billion KRW | 0.0% |
| 2015 FY | 124.56 Billion KRW | 0.0% |
| 2014 Q2 | 124.56 Billion KRW | 0.0% |
| 2014 Q1 | 124.56 Billion KRW | 0.0% |
| 2014 Q3 | 124.56 Billion KRW | 0.0% |
| 2014 FY | 124.56 Billion KRW | 0.0% |
| 2014 Q4 | 124.56 Billion KRW | 0.0% |
| 2013 FY | 124.56 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | -355.419% |
| Yuhan Corporation | 230.07 Billion KRW | 4.48% |
| Yuhan Corporation | 230.07 Billion KRW | 4.48% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -457.675% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -457.675% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -457.675% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 42.479% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | -24.952% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 68.237% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -29.06% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -29.06% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -29.06% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -36804.979% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 53.045% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | -407.857% |
| HANDOK Inc. | 300.01 Billion KRW | 26.748% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | -27.009% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -616.728% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | -176.826% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | -21.418% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -92188.91% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | -50.472% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | -228.584% |
| Boryung Corporation | 204.21 Billion KRW | -7.614% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -460.552% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | -85.239% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -158.061% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -158.061% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 53.028% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 6.738% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -16928.968% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -34671.363% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | -142.881% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -376.18% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -376.18% |
| Korea United Pharm Inc. | 40.33 Billion KRW | -444.792% |
| CKD Bio Corp. | 146.92 Billion KRW | -49.574% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 53.21% |
| JW Holdings Corporation | 554.58 Billion KRW | 60.373% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 2.35% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 61.638% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 45.965% |
| JW Lifescience Corporation | 46.31 Billion KRW | -374.521% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | -0.883% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | -158.65% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -728.264% |